These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36452015)

  • 1. The Melbourne epidemic thunderstorm asthma event 2016: a 5-year longitudinal study.
    Huang F; Wang DH; Foo CT; Young AC; Fok JS; Thien F
    Asia Pac Allergy; 2022 Oct; 12(4):e38. PubMed ID: 36452015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of asthma symptoms after epidemic thunderstorm asthma: a 3-year longitudinal study.
    Foo CT; Fernando S; Cohen N; Adabi G; Lim CMT; Young AC; Thien F
    Asia Pac Allergy; 2020 Jul; 10(3):e30. PubMed ID: 32789115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continued loss of asthma control following epidemic thunderstorm asthma.
    Foo CT; Yee EL; Young A; Denton E; Hew M; O'Hehir RE; Radhakrishna N; Matthews S; Conron M; Harun NS; Lachapelle P; Douglass JA; Irving L; Lee J; Stevenson W; McDonald CF; Langton D; Banks C; Thien F
    Asia Pac Allergy; 2019 Oct; 9(4):e35. PubMed ID: 31720246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The perfect storm: temporal analysis of air during the world's most deadly epidemic thunderstorm asthma (ETSA) event in Melbourne.
    Price D; Hughes KM; Dona DW; Taylor PE; Morton DAV; Stevanovic S; Thien F; Choi J; Torre P; Suphioglu C
    Ther Adv Respir Dis; 2023; 17():17534666231186726. PubMed ID: 37646293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thunderstorm asthma: revealing a hidden at-risk population.
    Clayton-Chubb D; Con D; Rangamuwa K; Taylor D; Thien F; Wadhwa V
    Intern Med J; 2019 Jan; 49(1):74-78. PubMed ID: 29573176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing Exacerbations in Thunderstorm Asthma: Current Insights.
    Chatelier J; Chan S; Tan JA; Stewart AG; Douglass JA
    J Inflamm Res; 2021; 14():4537-4550. PubMed ID: 34526800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
    Larenas-Linnemann D
    Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thunderstorm-triggered asthma: what we know so far.
    Harun NS; Lachapelle P; Douglass J
    J Asthma Allergy; 2019; 12():101-108. PubMed ID: 31190900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.
    Dranitsaris G; Ellis AK
    J Eval Clin Pract; 2014 Jun; 20(3):225-38. PubMed ID: 24444390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An epidemic of thunderstorm asthma in Melbourne 2016: asthma, rhinitis, and other previous allergies.
    Rangamuwa KB; Young AC; Thien F
    Asia Pac Allergy; 2017 Oct; 7(4):193-198. PubMed ID: 29094016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update about Oralair® as a treatment for grass pollen allergic rhinitis.
    Klimek L; Brehler R; Mösges R; Demoly P; Mullol J; Wang DY; O'Hehir RE; Didier A; Kopp M; Bos C; Karagiannis E
    Hum Vaccin Immunother; 2022 Nov; 18(5):2066424. PubMed ID: 35704772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemic Thunderstorm Asthma: Lessons Learned from the Storm Down-Under.
    Price D; Hughes KM; Thien F; Suphioglu C
    J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1510-1515. PubMed ID: 33172604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors.
    Thien F; Beggs PJ; Csutoros D; Darvall J; Hew M; Davies JM; Bardin PG; Bannister T; Barnes S; Bellomo R; Byrne T; Casamento A; Conron M; Cross A; Crosswell A; Douglass JA; Durie M; Dyett J; Ebert E; Erbas B; French C; Gelbart B; Gillman A; Harun NS; Huete A; Irving L; Karalapillai D; Ku D; Lachapelle P; Langton D; Lee J; Looker C; MacIsaac C; McCaffrey J; McDonald CF; McGain F; Newbigin E; O'Hehir R; Pilcher D; Prasad S; Rangamuwa K; Ruane L; Sarode V; Silver JD; Southcott AM; Subramaniam A; Suphioglu C; Susanto NH; Sutherland MF; Taori G; Taylor P; Torre P; Vetro J; Wigmore G; Young AC; Guest C
    Lancet Planet Health; 2018 Jun; 2(6):e255-e263. PubMed ID: 29880157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimum treatment strategies for polyallergic patients - analysis of a large observational trial.
    Shah-Hosseini K; Mioc K; Hadler M; Karagiannis E; Mösges R
    Curr Med Res Opin; 2015 Dec; 31(12):2249-59. PubMed ID: 26366617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience.
    Didier A; Wahn U; Horak F; Cox LS
    Expert Rev Clin Immunol; 2014 Oct; 10(10):1309-24. PubMed ID: 25205329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
    JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who's at risk of thunderstorm asthma? The ryegrass pollen trifecta and lessons learnt from the Melbourne thunderstorm epidemic.
    Lee J; Kronborg C; O'Hehir RE; Hew M
    Respir Med; 2017 Nov; 132():146-148. PubMed ID: 29229087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thunderstorm asthma: an overview of mechanisms and management strategies.
    Thien F; Davies JM; Hew M; Douglass JA; O'Hehir RE
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1005-1017. PubMed ID: 32960102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy.
    Valovirta E; Petersen TH; Piotrowska T; Laursen MK; Andersen JS; Sørensen HF; Klink R;
    J Allergy Clin Immunol; 2018 Feb; 141(2):529-538.e13. PubMed ID: 28689794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
    Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
    JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.